Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Inflammation01:38

Inflammation

Overview
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.

Leukemia·2025
Same author

[A man in his 30s with psychosis and neutropenia].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2025
Same author

Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.

British journal of haematology·2025
Same author

Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial.

Haematologica·2025
Same author

A patient with minimal myeloma treatment who survived for 20 years.

Haematologica·2023
Same author

Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia.

Acta oncologica (Stockholm, Sweden)·2023

Related Experiment Video

Updated: Jun 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins and inflammation: an update.

Petter Quist-Paulsen1

  • 1Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. petter.quist-paulsen@stolav.no

Current Opinion in Cardiology
|April 28, 2010
PubMed
Summary

Statins offer cardiovascular benefits beyond cholesterol reduction, including anti-inflammatory and anti-clotting effects. These non-lipid mechanisms likely contribute to their overall effectiveness in reducing cardiovascular risk.

Related Experiment Videos

Last Updated: Jun 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Statins are primarily known for cholesterol reduction.
  • Emerging evidence suggests statins possess non-lipid-lowering cardiovascular benefits.
  • These effects may involve anti-inflammatory and anti-thrombotic pathways.

Purpose of the Study:

  • To review the non-lipid-mediated effects of statins.
  • To evaluate the clinical significance of these non-lipid effects on cardiovascular outcomes.

Main Methods:

  • Review of randomized trials and investigations on statin mechanisms.
  • Analysis of inflammatory markers (e.g., C-reactive protein) and clotting factors.
  • Assessment of clinical outcomes related to statin therapy.

Main Results:

  • Statins reduce plasma markers of inflammation, such as C-reactive protein (CRP).
  • Statins decrease T-cell and monocyte activation and reduce blood clotting.
  • These effects are potentially mediated by the inhibition of L-mevalonic acid synthesis.
  • Statins significantly reduce the risk of venous thrombosis, likely through non-lipid mechanisms.

Conclusions:

  • Statins possess clinically important anti-inflammatory properties that lower cardiovascular risk.
  • A portion of statins' benefits may stem from their non-lipid-lowering effects, although this is not definitively proven.